Abstract: A sustained release Venlafaxine composition that includes a plurality of non-agglomerated, uniformly-shaped and sized microbeads of inert core particles having a first coating layer. The first coating layer includes an active agent of Venlafaxine or a pharmaceutical acceptable salt thereof, a binder, and an anti-tack agent. The active agent is present in the first coating layer in a concentration of at least about 5% to about 70% by weight of the composition, the binder is present in an amount of at least 35% by weight of the active agent, or in a further layer located upon or below the first coating layer, or as an alternating layer between plural first layers, wherein the binder is present in an amount of less than about 2.5% by weight of the composition, and the anti-tack agent is present in the first coating layer in a concentration of about 2.5% to about 20% by weight based on the weight of the active agent. The composition is also substantially free of organic acid.

Abstract: A novel patient-convenient, cost effective pharmaceutical composition, comprising of thiazolidinediones and biguanide for controlling hyperglycemia manufactured as multilayer tablet and its process of manufacturing, for immediate release of thiazolidinediones or thiazolidinediones and biguanide and prolonged release of the biguanide only, the tablet comprising of minimum two layers wherein one outer layer comprises of a mixture of excipients and thiazolidinediones or thiazolidinediones and biguanide allowing immediate release of thiazolidinediones or thiazolidinediones and biguanide respectively and the other layer arranged in contact with the immediate release layer which comprises of a novel composition of excipients and a minimum one or more non-biodegradable, inert polymer(s) and the biguanide allowing pH independent prolonged release of the biguanide up to a period of 8-12 hours. The tablets are for once a day dosing.

Abstract: This invention relates to a process for the manufacture of a stable, oral, multiple unit pharmaceutical composition containing high concentrations of benzimidazole up to about 35 to 45% w/w, preferably up to about 40% w/w, a disintegrating agent, and one or more fillers. Surfactants in these compositions are in an enteric polymer layer and preferably not in contact with the benzimidazole. The process preferably involves sequential deposition of: (a) an alkaline material layer on non-pariel seeds to obtain treated non-pariel seeds; (b) a drug layer of the benzimidazole to obtain drug pellets; (c) a sealant polymer layer to obtain sealed pellets; and (d) an enteric polymer layer to obtain enteric-coated pellets.